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least once by a substantial percentage of persons in this study.
These data provide insight into care for persons at the end of
life, particularly among persons with cancer. Furthermore, this
information may be useful as a process indicator of the quality
of end of life care.
GASTROINTESTINAL DISORDERS—Cost Studies
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OBJECTIVES: To estimate: (i) the current rotavirus burden in
New Zealand children less than 5 years of age; and (ii) the annual
health beneﬁts, budget impact and cost- effectiveness of includ-
ing Rotateq, a pentavalent live-attenuated oral rotavirus vaccine,
in the annual Childhood Immunisation Schedule. METHODS:
A spreadsheet model was based on local epidemiology and costs
plus the ﬁndings of a large phase III clinical trial showing that
RotaTeq had 94.5% efﬁcacy against rotavirus hospital presen-
tations and 86.0% against non-urgent medical visits. In the base
case, vaccine uptake was 85% and the annual discount rate was
5%. RESULTS: We predict annually 1356 admissions, 2781 ED
presentations and 9495 primary-care consultations at an annual
societal cost of $7.8M ($27.68/child; two-thirds Government,
one-third caregivers). Vaccinating successive birth cohorts
becomes increasingly effective and cost-effective as more children
become immune. After ﬁve years (assuming 85% annual uptake
of 3 doses), 7936 cases seeking medical attention (1105 admis-
sions, 2215 ED presentations, 6941 primary-care consultations)
would be averted. At an acquisition cost of $50/dose, the incre-
mental cost to Government is $6.41 M in year-1 and $3.35 M in
year-5. Societal cost in year-5 would be $1301 to avert one hos-
pitalisation and $139 to avert one health care presentation. The
annual cost to Government is $3.38 M to avert 7936 cases of
paediatric rotavirus gastroenteritis that would otherwise require
medical attention. The incremental cost and cost/admission
averted are moderately sensitive to rotavirus incidence rates,
declining protection over 5 years (if any), and vaccine unit price,
but robust to uncertainty in other parameters. The budget impact
of vaccination will lessen slightly and the cost-effectiveness will
improve slightly beyond year-5, provided protective efﬁcacy is
maintained in school-aged children. CONCLUSION: Addition
of a pentavalent rotavirus vaccine to the New Zealand Child-
hood Immunisation Schedule would confer important clinical
gains at a modest annual cost.
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OBJECTIVES: To investigate the cost-effectiveness of therapy of
chronic hepatitis C with peginterferon alfa-2b and ribavirin in
the context of the Slovak health care system. METHODS: We
retrospectively obtained clinical data on the cost of treatment in
140 patients with chronic hepatitis C or advanced chronic liver
disease of other etiology. Life-time cost of untreated and treated
chronic hepatitis C was calculated using the Markov model and
cost-effectiveness of antiviral therapy was evaluated by cost per
life-year saved (LYS) analysis. RESULTS: The average medical
cost per patient-year in case of chronic hepatitis C not treated
with antiviral drugs, compensated cirrhosis, complicated cirrho-
sis, and after liver transplantation was 578 USD Sk (33,50 Slovak
crowns = 1 USD), 926 USD, 5890 USD, and 9997 USD, respec-
tively. The cost per life-year saved using 3% discounting was
3156 USD in the average group of patients and 5711 USD in
patients with genotype 1. In patients with genotype 2 and 3
antiviral treatment would result in a life-time cost saving of 492
USD per patient. CONCLUSION: The cost of treatment of
chronic hepatitis C and other chronic liver diseases in Slovakia
is comparable with countries with more advanced economies.
The treatment of chronic hepatitis C with peginterferon alfa-2b
and ribavirin in Slovakia is cost-effective based on pharma-
coeconomic calculations.
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OBJECTIVES: To study the impact of post-operative ileus (POI)
on health care utilization and costs in colectomy surgery patients
in the United States. METHODS: A retrospective cohort study
design was used. Adult patients with a principal procedure code
for colectomy (ICD-9 codes 45.71–45.79), discharged between
Jan. 2004 and Dec. 2004 were identiﬁed from Premier’s Per-
spective Comparative Database, an inpatient records database
from over 500 hospitals in the United States. The colectomy
patients were further classiﬁed for the presence of POI, deﬁned
as presence of paralytic ileus (ICD-9 code 560.1) and/or diges-
tive system complications (ICD-9 code 994.1) during the study
period. Hospital length of stay (LOS), ICU LOS, ventilator
usage, and hospitalization costs were compared using t-tests and
chi-square tests as appropriate. RESULTS: A total of 17,896
patients with primary procedure code for colectomy were iden-
tiﬁed, of which 3115 (17.4%) patients were classiﬁed for pres-
ence of POI, including paralytic ileus (N = 2732; 15.3%) and
digestive system complications (N = 1899; 10.6%), with signif-
icant overlap between the two (N = 1516; 8.5%). A majority of
the patients with POI were male (54.9%), caucasian (70.9%)
and in the 51–64 year age group (51%). The average hospital
LOS was signiﬁcantly higher (p < 0.001) in patients with 
POI (13.6 ± 13.3 days) compared with patients without POI 
(8.6 ± 9.5 days). The average ICU LOS was signiﬁcantly higher
(p < 0.001) in patients with POI (2.4 ± 8.6 days) compared 
with patients without (1.2 ± 9.5 days). Ventilator usage 
was found to be signiﬁcantly higher (p < 0.001) in the POI 
group (17.0%) compared to those without (12.4%). Average
hospitalization costs were signiﬁcantly higher (p < 0.001) in the
patients with POI ($25,089 ± 35,386) than those without POI
($16,907 ± 29,320). CONCLUSION: Post-operative ileus in
colectomy patients is associated with increased hospital resource
utilization. Prevention of POI could reduce hospital length of
stay and costs.
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